TRAVERE THERAPEUTICS, INC. (TVTX) Return on equity 2016–2025
TRAVERE THERAPEUTICS, INC. (TVTX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-22.2%FY2025 · since FY2016: -15.6% → -22.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -22.2% | +522.0 pp |
| FY2024 | -544.3% | -488.8 pp |
| FY2023 | -55.5% | +594.4 pp |
| FY2022 | -649.9% | -590.3 pp |
| FY2021 | -59.6% | +20.6 pp |
| FY2020 | -80.2% | -14.0 pp |
| FY2019 | -66.2% | -33.9 pp |
| FY2018 | -32.3% | -11.9 pp |
| FY2017 | -20.4% | -4.8 pp |
| FY2016 | -15.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More TVTX financial trends
TVTX RevenueTVTX Net incomeTVTX Net marginTVTX Gross profitTVTX Gross marginTVTX Operating incomeTVTX Operating marginTVTX Operating cash flowTVTX Free cash flowTVTX Capital expendituresTVTX Stock buybacksTVTX Dividends paidTVTX Total assetsTVTX Total liabilitiesTVTX Shareholders’ equityTVTX overview →